BioNTech SE
BioNTech
BioNTech SE is a biopharmaceutical company that partnered with Chinese 3D drug-printing firm Triastek in July 2024 on a platform technology licensing deal valued at over $1.2 billion in total potential payments, per Yunqi Capital. The collaboration centers on developing oral RNA drugs using Triastek's 3D printing technology, with BioNTech paying $10 million upfront and Triastek eligible for milestone payments plus royalties . Elsewhere's corpus also notes BioNTech's earlier joint announcement with Pfizer on COVID-19 vaccine efficacy in November 2020 . Beyond these deal references, elsewhere does not hold a dedicated profile of BioNTech SE's broader business or history.
AI-generated — may contain errors, please verify.
Coverage
On the Eve of IPO, a Conversation with METiS Pharmaceuticals' Caida Lai: From Formulas on a Whiteboard to "The SpaceX of Pharma"
The story behind the investment.
峰瑞资本·Yunqi Capital Quarterly | We Are Stardust, Imagining the Universe
New Practices, New Breakthroughs, New Thinking for Summer and Fall
云启资本·Over $1.2 Billion in Total Value: Triastek Announces First-Ever Technology Platform International Collaboration in Chinese Pharmaceutical History with BioNTech | Yunqi Capital
Empowering Digital Transformation in Pharmaceutical Development
云启资本·Li Feng in Conversation with Academician Shao Feng: First In Class in China | Last 2 Days to Register
How can basic biomedical research better connect with industry?
峰瑞资本·
